Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial

Life Science Investing News

Abeona Therapeutics, a clinical-stage biopharmaceutical company focused on delivering gene therapy for life-threatening rare diseases, announced that the fifth patient was enrolled in the Phase 1/2 clinical trial for EB-101 (gene-corrected skin grafts).

NEW YORK, NY and CLEVELAND, OH–(Marketwired – September 08, 2016) – Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy for life-threatening rare diseases, announced that the fifth patient was enrolled in the Phase 1/2 clinical trial for EB-101 (gene-corrected skin grafts).
According to the news release:

The Phase 1/2 clinical trial with gene-corrected skin grafts has shown promising wound healing and safety in patients with RDEB. Investigators at Stanford are now expanding enrollment to adolescent patients for the Phase 1/2 trial to determine the safety and efficacy of COL7A1 gene-corrected grafts on wound healing efficacy.

Click here to read the full news release.

abeona therapeutics enrollment gene therapy orphan diseases rare diseases Company News